Freeessaysample

Binge Eating Disorder (BED) Case Study

Binge Eating Disorder (BED) Case Study

#133727207

Topic:

Binge Eating Disorder (BED)

Type of paper:

Coursework

Discipline:

Health Care and Life Sciences : Nursing

Format or citation style:

APA

Pages: 1

Deadline: 5hrs

Discuss Binge Eating Disorder (BED) and the psychopharmacologic treatments that are available. Compare and contrast this treatment by providing evidence for its approval, comment on the strength of this evidence, and alternative, non-pharmacological treatments. How will you approach treatment for a patient with a newly diagnosed BED?

Please see this article
Citation: Granje (2018) Binge Eating Disorder (BED): Nutritional Prevention and Treatment. J Food Nutr Disor 7:2. doi: 10.4172/2324-9323.1000248
Binge Eating Disorder (BED):Nutritional Prevention and Treatment
Minimal 3 peer review references

Binge Eating Disorder (BED)

Student’s Name

Institutional Affiliations

Binge Eating Disorder (BED)

Binge Eating Disorder (BED) is the most prevalent eating disorder individuals eat excessive food amounts without compensatory strategies, lose control over the type and amount eaten but then followed by feelings of disgust and shame (Granje, 2018). The BED treatment might be of weight-related issues and psychiatric conditions given the resulting anxiety and affective disorders. The psychopharmacologic treatments for BED aim at reducing body weight and binges. They include the use of stimulants, antidepressants, and mood stabilizers.

Stimulants; Lisdexamfetamine is a pro-drug that influences the hedonic system and up-regulates CART expressions. It was approved in the US for treating adults with moderate to severe BED after studies established its superiority over placebo in reducing symptoms of obsessive-compulsive binge eating, binge eating days and body weight within four weeks of induction (Himmerich & Treasure, 2017).

Antidepressants: they are crucial in decreasing the binge seizure frequency and suppressing anxiety and depression symptoms for those with BED. They include noradrenaline reuptake inhibitors SNRIs, serotonin reuptake inhibitors SSRIs, and sibutramine; although it has been withdrawn recently from the US and European markets. Treatment with SSRIs is more effective for reduction in binge crisis that when placebo is used (Milano et al., 2013).

Mood stabilizers: Topiramate and zonisamide influence binge eating and weight loss. Studies indicate that topiramate reduces the frequencies of the binge episodes while improving the patient’s psychiatric comorbidity (Milano et al., 2013). However, some adverse effects might be experienced hence controlled intake.

Nutrition prevention and treatment: BED treatment can incorporate both psychological and nutrition interventions for improved efficacy. Nutrition management improves eating habits and assists in binge eating remission and weight reduction given the direct or indirect association of periodic compulsive eating disorder with nutrition (Granje, 2018). Therefore, equipping the patients with health information empowers them to take charge over their eating habits and with complementation of other strategies, then the BED treatment is accomplished.

Most of the evidence for the treatment strategies employed in BED is based on randomized controlled trials where significant limitations are present in each strategy. Therefore, while establishing the best treatment plans for individuals with newly diagnosed BED, background and follow-up checks should be contained to ensure the patient is nor adversely affected by the treatment plan.

References

Granje (2018) Binge Eating Disorder (BED): Nutritional Prevention and Treatment. J Food Nutr Disor 7:2. doi: 10.4172/2324-9323.1000248

Himmerich, H., & Treasure, J. (2017). Psychopharmacological advances in eating disorders. Expert review of clinical pharmacology, 11(1), 95-108. doi: 10.1080/17512433.2018.1383895

Milano, W., De Rosa, M., Milano, L., Riccio, A., Sanseverino, B., & Capasso, A. (2013). The pharmacological options in the treatment of eating disorders. ISRN pharmacology, 2013, 352865. doi:10.1155/2013/352865

Browse more products here

Order Here

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.